Cargando…
Efficacy and safety of glycyrrhizic acid preparation treating comorbid liver injury in COVID-19: A systematic review
Background: No specific drug for COVID-19 has been found, and many studies have found that different degrees of liver injury often occurred after infection with COVID-19. Glycyrrhizic acid preparation (GAP) has been frequently used clinically, often combined with conventional treatments such as anti...
Autores principales: | Liu, Xu, Tian, Xia, Ma, Zhipeng, Chen, Jiali, Huang, Qingsong, Gao, Peiyang, Zhang, Chuantao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9669476/ https://www.ncbi.nlm.nih.gov/pubmed/36408213 http://dx.doi.org/10.3389/fphar.2022.1003697 |
Ejemplares similares
-
Clinical efficacy and security of glycyrrhizic acid preparation in the treatment of anti-SARS-CoV-2 drug-induced liver injury: a protocol of systematic review and meta-analysis
por: Tian, Xia, et al.
Publicado: (2021) -
Advances in the roles of glycyrrhizic acid in cancer therapy
por: Zhang, Yuqian, et al.
Publicado: (2023) -
Glycyrrhizic Acid: A Natural Plant Ingredient as a Drug Candidate to Treat COVID-19
por: Sun, Zhong, et al.
Publicado: (2021) -
Glycyrrhizic acid alleviates bleomycin-induced pulmonary fibrosis in rats
por: Gao, Lili, et al.
Publicado: (2015) -
Transcriptome and Lipid Metabolomics-Based Discovery: Glycyrrhizic Acid Alleviates Tripterygium Glycoside Tablet-Induced Acute Liver Injury by Regulating the Activities of CYP and the Metabolism of Phosphoglycerides
por: Shi, Qiaoli, et al.
Publicado: (2022)